Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterated a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a $31 price target.
April 10, 2024 | 9:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reiterated a Buy rating on Nurix Therapeutics and maintained a $31 price target.
The reiteration of a Buy rating and maintenance of a $31 price target by a reputable analyst suggests a positive outlook for Nurix Therapeutics. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100